To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
Conditions: Langerhans Cell Histiocytosis; LCH Intervention: Drug: FCN-159 Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials